SpringWorks Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SpringWorks Therapeutics's estimated annual revenue is currently $35M per year.
- SpringWorks Therapeutics received $103.0M in venture funding in September 2017.
- SpringWorks Therapeutics's estimated revenue per employee is $91,864
- SpringWorks Therapeutics's total funding is $230M.
- SpringWorks Therapeutics's current valuation is $3.1B. (January 2022)
Employee Data
- SpringWorks Therapeutics has 381 Employees.
- SpringWorks Therapeutics grew their employee count by 15% last year.
SpringWorks Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
3 | Chief Staff | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | CEO | Reveal Email/Phone |
6 | Head Drug Discovery | Reveal Email/Phone |
7 | SVP, Global Pharmacovigilance | Reveal Email/Phone |
8 | Head Research And Development | Reveal Email/Phone |
9 | VP, Controller | Reveal Email/Phone |
10 | VP, Head Clinical Operations | Reveal Email/Phone |
SpringWorks Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is SpringWorks Therapeutics?
SpringWorks Therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. Originally conceived by Pfizer, SpringWorks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. Through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. Our name is a reflection of our approach to drug development: we're springing into action to deliver treatments to people who are in great need and without alternatives.
keywords:N/A$230M
Total Funding
381
Number of Employees
$35M
Revenue (est)
15%
Employee Growth %
$3.1B
Valuation
N/A
Accelerator
SpringWorks Therapeutics News
SpringWorks Therapeutics (NASDAQ:SWTX) Rating Lowered to Sell at Zacks Investment Research. Posted by admin on Apr 28th, 2022.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing...
Analysts Expect SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Will Post Earnings of -$1.07 Per Share. Posted by admin on Apr 17th, 2022.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $111.4M | 381 | -6% | N/A |
#2 | $47.6M | 381 | 6% | N/A |
#3 | $35M | 381 | N/A | N/A |
#4 | $35M | 381 | 9% | N/A |
#5 | $61.9M | 381 | 0% | N/A |
SpringWorks Therapeutics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2017-09-26 | $103.0M | A | Multiple | Article |